secwatch.observer — SEC 8-K summary
======================================

Issuer:     PRECISION BIOSCIENCES INC (DTIL)
CIK:        0001357874
Form:       8-K
Filed at:   2026-08-06T11:16:15+00:00
Accession:  0001628280-26-053836
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Precision BioSciences reports first clinical evidence of cccDNA elimination in HBV; Q2 net loss $32.7M
--------------------------------------------------------------------------------

- Liver biopsy showed 1-log reduction in cccDNA with <1% remaining after two PBGENE-HBV doses.
- pgRNA became undetectable in 100% of evaluable patients; sustained up to six months.
- Cash balance $112.4M as of June 30, 2026; expected to fund milestones through 2028.
- Net loss $32.7M ($1.26/share) vs $23.5M ($2.13/share) in Q2 2025; non-cash warrant loss drove increase.
- Alex Kelly promoted to COO; Naresh Tanna promoted to CFO; Cassie Gorsuch now leads all research.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/0001628280-26-053836-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/dtil-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-053836

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer